Mirum Pharmaceuticals price target raised to $66 from $58 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Mirum Pharmaceuticals to $66 from $58 and keeps a Buy rating on the shares after the company announced interim results from the Phase 2b VANTAGE study evaluating volixibat for the treatment of primary biliary cholangitis, or PBC. The firm views volixibat’s efficacy in PBC as “highly encouraging given the small sample size that we view with a well-balance baseline profile” and notes that management believes that positive pruritus improvements would sufficiently support volixibat’s approval for both PBC and primary sclerosing cholangitis, or PSC.